If you or someone you know has been diagnosed with metastatic breast cancer, please read the following:

* Directly contact or have your doctor contact your nearest clinical site listed on ClinicalTrials.gov as summarized below:

* In a clinical study of 54 patients, Bria-IMT regimen used in combination with an immune check point inhibitor was associated with longer than expected progression free survival and other clinical benefits in metastatic breast cancer patients. The treatment was well-tolerated.

If you have any questions or concerns, please have your oncologist contact us ([email protected]).

Bria-ABC Study (Uses Bria-IMT)

Study Name:

BriaCell Therapeutics Corp. / Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

The combination study is listed on ClinicalTrials.gov as NCT06072612.

———————————————————————————————————————

BC1 Study (Uses Bria-OTS)

Study Name:

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06471673

 

Why Clinical Trials Matter

When you or your loved one face a diagnosis of metastatic breast cancer, hope can feel far away. But clinical trials offer a path forward. Better yet, it’s one grounded in science, compassion, and the search for better outcomes. For patients living with advanced breast cancer, enrolling in a clinical trial can provide access to emerging treatments before they become widely available.

Clinical trials play a shaping role in achieving the future of breast cancer care. These studies allow researchers to test new therapies, refine existing ones, and better understand how to target the disease. For metastatic breast cancer patients, clinical research is especially important because it can open the door to innovative treatment strategies that may offer new hope when other options have been exhausted.

Participating in a breast cancer clinical trial brings several benefits:

  • Access to innovative treatments. Trials may include therapies not available outside of the study, including the latest immunotherapy for breast cancer.
  • Enhanced medical oversight. Patients in clinical trials are closely monitored by experienced medical teams who track their progress and adjust treatment as needed.
  • Contribution to science. Each participant helps advance our understanding of metastatic breast cancer and brings us closer to future cures.

Above all, clinical trials are designed with patient safety and ethics at the forefront. Every trial must follow strict guidelines approved by regulatory and oversight bodies. This means our care teams are not only focused on outcomes but also on dignity, comfort, and transparency at every step.

BriaCell’s Approach: Immunotherapy for Breast Cancer

At BriaCell, we’re working to rewrite the story of metastatic breast cancer. Our focus is on immunotherapy, which is a groundbreaking approach that helps the body’s own immune system recognize and fight cancer more effectively. It’s a promising shift from traditional treatments like chemotherapy, which can be harsh on the body and non-specific in targeting cancer cells.

Our lead candidate, Bria-IMT™, is an innovative immunotherapy specifically developed for breast cancer. It’s designed to stimulate the immune system to recognize breast cancer cells and launch a targeted attack against them. This patient-friendly therapy aims to work in harmony with the body’s natural defenses.

In our clinical trials, we explore how Bria-IMT™ performs alongside checkpoint inhibitors and other immune-based agents to boost its effectiveness. The goal is to find the most responsive treatment combinations based on each patient’s unique immune profile.

Here’s where we stand now:

  1. Active research. We are conducting multiple breast cancer clinical trials to evaluate Bria-IMT™ in patients with advanced disease.
  2. Encouraging data. Preliminary findings suggest that Bria-IMT™ may improve outcomes, particularly for certain subtypes of metastatic breast cancer patients.
  3. Ongoing enrollment. We are currently enrolling breast cancer trials for eligible patients seeking alternatives to standard care.

If you or someone you love is facing metastatic breast cancer, we understand the weight of that journey. Our mission is to provide not only scientific innovation but also compassionate support for patients and families navigating these challenges. We believe every person deserves access to promising new options, and we’re committed to making those options a reality.

We invite you to explore our ongoing clinical trials and learn more about whether immunotherapy through BriaCell may be right for your situation. Together, we’re not just researching, we’re fighting for a future where metastatic breast cancer can be managed more effectively, with greater hope and better outcomes for all.